1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chelsea Therapeutics International Ltd. – Product Pipeline Review – 2013

Chelsea Therapeutics International Ltd. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013” provides data on the Chelsea Therapeutics International Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Chelsea Therapeutics International Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Chelsea Therapeutics International Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Chelsea Therapeutics International Ltd. - Brief Chelsea Therapeutics International Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Chelsea Therapeutics International Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Chelsea Therapeutics International Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Chelsea Therapeutics International Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Chelsea Therapeutics International Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Chelsea Therapeutics International Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Chelsea Therapeutics International Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Chelsea Therapeutics International Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Chelsea Therapeutics International Ltd. and identify potential opportunities in those areas.

Table Of Contents

Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Chelsea Therapeutics International Ltd. Snapshot 5
Chelsea Therapeutics International Ltd. Overview 5
Key Information 5
Key Facts 5
Chelsea Therapeutics International Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Chelsea Therapeutics International Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Chelsea Therapeutics International Ltd. - Pipeline Products Glance 11
Chelsea Therapeutics International Ltd. - Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Chelsea Therapeutics International Ltd. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Chelsea Therapeutics International Ltd. - Drug Profiles 15
(droxidopa + carbidopa) 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
CH-4051 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
droxidopa 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Chelsea Therapeutics International Ltd. - Pipeline Products by Route of Administration 20
Chelsea Therapeutics International Ltd. - Pipeline Products By Mechanism of Action 21
Chelsea Therapeutics International Ltd. - Recent Pipeline Updates 22
Chelsea Therapeutics International Ltd. - Dormant Projects 30
Chelsea Therapeutics International Ltd. - Discontinued Pipeline Products 31
Discontinued Pipeline Product Profiles 31
ABR-224050 31
CH-1504 31
Chelsea Therapeutics International Ltd. - Company Statement 32
Chelsea Therapeutics International Ltd. - Locations And Subsidiaries 37
Head Office 37
Chelsea Therapeutics International Ltd., Recent Developments 38
Chelsea Therapeutics International Ltd.- Press Release 38
Sep 27, 2010: Chelsea Initiates CH-4051 Phase II Trial In Rheumatoid Arthritis 38
Aug 26, 2010: Chelsea Receives FDA Approval Of CH-4051 Phase II Protocol 39
Jun 29, 2010: Chelsea Provides Update On Status Of Phase II Study Of CH-4051 In Rheumatoid Arthritis 40
Feb 11, 2010: Chelsea Therapeutics Initiates Phase II Trial Of Droxidopa In Combination With Carbidopa In Adult Attention Deficit Hyperactivity Disorder 40
Financial Deals Landscape 42
Chelsea Therapeutics International Ltd., Deals Summary 42
Chelsea Therapeutics International Ltd., Pharmaceuticals and Healthcare, Deal Details 43
Equity Offering 43
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of $100 Million 43
Chelsea Therapeutics Completes Public Offering Of Common Stock For $24 Million 45
Chelsea Therapeutics International Completes Public Offering Of Its Common Stock For $40.3 Million 47
Chelsea Therapeutics International Completes Public Offering Of $40 Million 49
Chelsea Therapeutics International Completes Registered Direct Offering Of $18.22 Million 51
Chelsea Therapeutics Completes Public Offering Of $13.3 Million 53
Chelsea Therapeutics International Completes Private Placement Of $48.9 Million 55
Chelsea Therapeutics International Completes Private Placement Of $12.5 Million 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60



List of Tables

Chelsea Therapeutics International Ltd., Key Information 5
Chelsea Therapeutics International Ltd., Key Facts 5
Chelsea Therapeutics International Ltd. - Pipeline by Indication, 2013 7
Chelsea Therapeutics International Ltd. - Pipeline by Stage of Development, 2013 8
Chelsea Therapeutics International Ltd. - Monotherapy Products in Pipeline, 2013 9
Chelsea Therapeutics International Ltd. - Combination Treatment Modalities in Pipeline, 2013 10
Chelsea Therapeutics International Ltd. - Filed, 2013 11
Chelsea Therapeutics International Ltd. - Phase III, 2013 12
Chelsea Therapeutics International Ltd. - Phase II, 2013 13
Chelsea Therapeutics International Ltd. - Phase I, 2013 14
Chelsea Therapeutics International Ltd. - Pipeline By Route of Administration, 2013 20
Chelsea Therapeutics International Ltd. - Pipeline Products By Mechanism of Action, 2013 21
Chelsea Therapeutics International Ltd. - Recent Pipeline Updates, 2013 22
Chelsea Therapeutics International Ltd. - Dormant Developmental Projects,2013 30
Chelsea Therapeutics International Ltd. - Discontinued Pipeline Products, 2013 31
Chelsea Therapeutics International Ltd., Deals Summary 42
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of $100 Million 43
Chelsea Therapeutics Completes Public Offering Of Common Stock For $24 Million 45
Chelsea Therapeutics International Completes Public Offering Of Its Common Stock For $40.3 Million 47
Chelsea Therapeutics International Completes Public Offering Of $40 Million 49
Chelsea Therapeutics International Completes Registered Direct Offering Of $18.22 Million 51
Chelsea Therapeutics Completes Public Offering Of $13.3 Million 53
Chelsea Therapeutics International Completes Private Placement Of $48.9 Million 55
Chelsea Therapeutics International Completes Private Placement Of $12.5 Million 57



List of Figures

Chelsea Therapeutics International Ltd. - Pipeline by Indication, 2013 7
Chelsea Therapeutics International Ltd. - Pipeline by Stage of Development, 2013 8
Chelsea Therapeutics International Ltd. - Monotherapy Products in Pipeline, 2013 9
Chelsea Therapeutics International Ltd. - Combination Treatment Modalities in Pipeline, 2013 10
Chelsea Therapeutics International Ltd. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.